Individuals with a BMI of 30 or higher, or those with a BMI of 27 or higher who have weight-related health conditions, may be candidates for GLP-1 medications
This triggers systemic (system-wide) inflammation, increasing the risk for food sensitivities, inflammation, chronic pain, brain degeneration (brain fog), and autoimmune disease
Improvement of muscle mass is highly desirable in patients with diabetes, who are more prone to sarcopenia conditions
I was a little nervous I wasnt going to see results on my stomach but its working great
WeightCare does not accept insurance directly
Understanding proper peptide storage protocols helps maintain therapeutic potency throughout the product lifecycle